A Crossover Study to Evaluate Amantadine Steady-State Pharmacokinetics Following Oral Administration of ADS 5101, Amantadine HCl Extended Release (ER) Capsules, QD and the Amantadine HCl Immediate Release (IR) Tablets BID in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
At a glance
- Drugs Amantadine (Primary)
- Indications Neurological disorders; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Adamas Pharmaceuticals
- 18 May 2018 Results of pooled data from 2 phase1 trial and a phase 2/3 trial assessing pharmacokinetics of ADS-5102 (Amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia, were published in the Clinical Pharmacokinetics.
- 12 Feb 2010 New trial record